Viewing Company Stryker Corp. | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Stryker Corp. Stock Symbol: SYK-N

Notes:manufactures orthopedic equipment

Last Price Recorded: $134.4500 on 2017-04-24

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-03-16 TOP PICK Zachary Curry

This is known for knees and hips, and they have sold millions of knee replacement implants. They’ve recently started using a robot to replace the body parts, giving greater accuracy and lower costs. With the robot, you can only use their parts, making it a closed system. He doesn’t foresee any changes in the US health care act having an effect on this company and their equipment. Dividend yield of 1.3%. (Analysts’ price target is $132.)


Price:
$131.500
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2017-03-01 BUY Barry Schwartz

This is a business that people need to have exposure to. His clients own a similar company, Zimmer Biomet (ZBH-N) which manufactures replacements for hips, knees, and they do stuff for your back, dental. This is a business that unfortunately is going to do well as people age and live longer and wear out their useful parts. Hips and knee replacements is going to grow at a significant rate, and there are only a few companies that manufacture these things.


Price:
$131.050
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
No
2017-02-27 DON'T BUY James Thorne

It is an interesting space, but expensive.  Wait until we get clarity on what is happening with Obamacare.  Investors may migrate out of the devices group.


Price:
$128.580
Subject:
US DIVIDEND
Bias:
UNKNOWN
Owned:
Unknown
2017-02-22 BUY Paul Macdonald

This is a long-term Hold. He recently added to his holdings. This is your hip, knees, ankles, feet, prosthetics. You are paying a little bit more for their growth. This is going to be the wave of the future. Feels they are capturing market share.


Price:
$127.290
Subject:
HEALTHCARE
Bias:
BULLISH on HEALTH CARE
Owned:
Yes
2017-01-12 PAST TOP PICK Mohsin Bashir

(Top Pick Feb 25/16, Up 21.75%) He is not chasing high flying pharma, but the more steady, boring ones that people use more and more as they age.  They grow by acquisition. 


Price:
$123.260
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2016-11-15 DON'T BUY John Burke

When it comes to healthcare stocks, you have to differentiate between those pharmaceuticals that have very good margins without any threat to their profit margins, and a stock like this that makes implants. In the field of implants, there has been very little innovation in the last 10 years, and he thinks problems are going to come from both Medicare and Medicaid. Thinks they are going to be pushing prices down, not up, which is a threat to the implant manufacturers.


Price:
$109.740
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-08-31 PAST TOP PICK Mohsin Bashir

(A Top Pick Feb 25/16. Up 14.39%.) Hospital equipment. The growth drivers are charged by the demographics, but also having really high quality equipment, and making strategic acquisitions to integrate itself into the hospital industry structure in a better way. (Wouldn’t buy at current prices, but wait for a 10% pullback at least.)


Price:
$115.660
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2016-06-21 COMMENT Zachary Curry

Demographically this is really positive. Mr. Trump and Mrs. Clinton debate doesn’t factor into a company like this. They make knees and hips, and are into shoulders a bit now. They now include technology so that if a hip has problems, it can send a message. A little expensive, but a good grower and there is room for acquisitions.


Price:
$116.460
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2016-04-18 BUY Hap (Robert) Sneddon FCSI

Thinks this is a probably going to be a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out.


Price:
$110.390
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
UNKNOWN
Owned:
Unknown
2016-02-25 TOP PICK Mohsin Bashir

Healthcare is the only sector that has both top line and earnings growth.  Hospital beds, hip and knee replacements.  They are geared to the aging demographic.


Price:
$101.800
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2016-01-13 COMMENT Zachary Curry

This is down from its highs and is a good story.


Price:
$89.310
Subject:
NORTH AMERICAN - LARGE
Bias:
BEARISH
Owned:
Yes
2015-11-30 PAST TOP PICK John O'Connell, CFA

(A Top Pick Jan 28/14. Up 5.15%.) Loves the company. Very innovative. They are introducing more technology in the operating room. Not only providing the product that goes into your body, but also building the robot that assists the doctor that performed the surgery. Has a great 5 year track record of increasing its dividend. Good strong balance sheet. Strong international sales. Still a Buy.


Price:
$96.460
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2015-11-02 PAST TOP PICK Zachary Curry

(A Top Pick April 7/14. Up 21.7%.) The healthcare sector is kind of fragmented into biotech, pharmaceutical and equipment. His view on the equipment side is quite constructive. Demographics are positive. Also, you don’t have the regulatory side that you have with the drugs.


Price:
$96.710
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2015-04-01 PAST TOP PICK Zachary Curry

(A Top Pick April 7/14. Up 13.91%.) Part of this company is focused on technology. They are known as the knees and hips type of company. Going forward, this offers a ton of opportunities, anywhere from demographics to healthcare. Good balance sheet and good management team.


Price:
$91.180
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2015-01-28 TOP PICK John O'Connell, CFA

Joint replacements. A great international growth story. The rising middle class globally will be spending more money on health care, so it is a good longer-term global story. Strong balance sheet. Very high return on equity at around 18%-19% consistently. Growing their dividend at around 25% compounded over the last 3-4 years.


Price:
$92.750
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
Showing 1 to 15 of 38 entries
<< < 1 2 3 > >>

No Comments.


You must be logged in to comment.